EREG (epiregulin) is mainly known as a ligand of EGFR (epidermal growth factor receptor) and ErbB-4 (receptor tyrosine-protein kinase). It induces tyrosine phosphorylation of EGFR, ErbB-2, ErbB-3 and ErbB-4. The mechanism of action involves interaction with EGFR, dimerization of EGFR and induction of autophosphorylation. The EREG gene is mapped to human chromosome 4q13.
Recombinant human Epiregulin is a 5.6kDa monomeric protein, containing 50 amino residues, which corresponds to the mature secreted Epiregulin sequence.
Epiregulin human has been used as a supplement in media 199 to stimulate human epidermal keratinocytes. It has also been used to treat colon cancer cells to test its effect on cell migration.
Epiregulin human has been added in the culture medium to study the effect of epiregulin on epithelial invasion.
EREG (epiregulin)-mediated EGFR (epidermal growth factor receptor) phosphorylation is responsible for the activation of various pathways, including the mitogen-activated protein kinase (MAPK), phosphoinositide 3-kinase (PI3K) and STAT5 (signal transducer and activator of transcription 5) responses. These pathways are involved in proliferation, cell survival, and angiogenesis. EREG is upregulated in colon, breast and ovarian cancers.
MVAQVSITKC SSDMNGYCLH GQCIYLVDMS QNYCRCEVGY TGVRCEHFFL
Lyophilized with no additives.
Centrifuge the vial prior to opening. Reconstitute in water to a concentration of 0.1-1.0 mg/ml. Do not vortex. This solution can be stored at 2-8°C for up to 1 week. For extended storage, it is recommended to further dilute in a buffer containing a carrier protein (example 0.1% BSA) and store in working aliquots at -20°C to -80°C.